ECOR - ElectroCore Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
34%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 50.77%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -380.37%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 7.3
Debt Ratio is 0.14
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
ElectroCore Inc (ECOR) - www.electrocore.com
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.Exchange - NASDAQ
Industry - Electromedical and Electrotherapeutic Apparatus Manufacturing
Sector - Manufacturing
CEO -
Employees - 45
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.